Krol, Ilona
Castro-Giner, Francesc
Maurer, Martina
Gkountela, Sofia
Szczerba, Barbara Maria
Scherrer, Ramona
Coleman, Niamh http://orcid.org/0000-0002-5803-9528
Carreira, Suzanne
Bachmann, Felix
Anderson, Stephanie
Engelhardt, Marc
Lane, Heidi
Evans, Thomas Ronald Jeffry
Plummer, Ruth
Kristeleit, Rebecca
Lopez, Juanita
Aceto, Nicola
Funding for this research was provided by:
EC | European Research Council (ERC) (678834)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) (163938)
Article History
Received: 2 February 2018
Revised: 12 June 2018
Accepted: 25 June 2018
First Online: 1 August 2018
Competing interests
: The authors declare no competing interests.
: Research in the Aceto lab is supported by the European Research Council, the Swiss National Science Foundation, the Swiss Cancer League, the Basel Cancer League, Basilea Pharmaceutica International Ltd., the two Cantons of Basel through the ETH Zürich, and the University of Basel.
: Patients were participants in the GBM arm of the ongoing study ‘An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumours and in adult patients with recurrent or progressive glioblastoma or high-grade glioma’ (NCT02490800). The study was conducted in accordance with the Declaration of Helsinki (2000) and the International Conference on Harmonisation Guidelines for Good Clinical Practice. The study was approved by each study centre’s Research Ethics Committee and all patients provided written informed consent prior to enrollment. Mouse experiments were carried out according to institutional and cantonal guidelines (approved mouse protocol 2781, cantonal veterinary office of Basel-City).
: All patients enroled in the study have signed a written informed consent before enrolment and agreed to data publication in anonymised form.
: Exome-sequencing data have been deposited to the European Nucleotide Archive (ENA, EMBL-EBI) with the accession number PRJEB27438.